RetaMaps

Lone Star Medical Associates

Lone Star Medical Associates · 1645 Dorchester Drive · Plano, TX 75075

4.8· 320 Google reviews

Listing updated October 2, 2026

Retatrutide outlook for this practice

No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.

About this practice

Lone Star Medical Associates is an adult primary care practice in Plano, Texas, led by Dr. Muzakeer Shaik, whom its website describes as a board-certified geriatrician with advanced training in wound care. The site lists annual physicals, chronic disease management, same-day visits, telehealth and weight loss support. Google shows a 4.8-star rating across 320 reviews dating to 2024, with 90 in the past year. Reviewers most often mention the staff (36 reviews) and a caring approach, and 12 mention scheduling. The site doesn't name specific GLP-1 medications, so ask which weight-management options it offers.

Services & access

Advertises semaglutide todayNot listed
Advertises tirzepatide todayNot listed
Telehealth visitsYes
Cash pay accepted—
Accepts insurance — per practice websiteYes
Accepting new patients — per practice websiteYes

"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.

Review activity

★ 4.8
Google rating · 320 reviews
90
reviews in the past year (avg ★ 4.4)

Counts computed by RetaMaps from public Google reviews; most recent review 2026-09-24. Read the reviews themselves on the practice's Google listing.

What patients say

Rated ★4.8 across 320 Google reviews. Of the 100 reviews we analyzed, 85 (85%) are positive (4–5★) and 13 (13%) are negative (1–2★).

What patients like

  • Friendly, helpful staff32 reviews
  • Feeling listened to23 reviews
  • Knowledgeable, professional providers21 reviews
  • Easy scheduling and communication8 reviews

Common complaints

  • Staff or front-desk issues5 of 13 negative
  • Felt rushed or unheard4 of 13 negative
  • Billing, pricing or insurance problems4 of 13 negative
5★
80
4★
5
3★
2
2★
0
1★
13

Most recent Google reviews

Seth M.★★★★★2026-09-24

But have a visit scheduled for December, but I needed immediate assistance, so I called and had a video chat with the doctor just a few hours later that day. He percribed me the medicine I needed, and I went to CVS a few minutes later. Outstanding

Laith G.★★★★★2026-09-20

The best dr in the area they do Testosterone and Botox and Laser very good and you can do it any time is no appointment

John V.★★★★★2026-09-17

The facility is nice. The doctor and the staff are very friendly, helpful and professional. I highly recommend Lone Star Medical Associates Pllc.

Darrick M.★★★★★2026-09-17

Dr. Shaik and his staff were very patient and accommodating during my physical exam. My exam was very thorough and conducted with any delay.

Candi R.★★★★★2026-09-15

Honestly this is the only doctor who has actually listened then sent out a bunch of referrals instead of playing the waiting game and wasting a bunch of time. I love that he sent E-refferals instead of the ones in the mail!

Analysis by RetaMaps of reviews on this practice's public Google Business listing; review themes are detected automatically and reviews reflect their authors' opinions. See all reviews on Google.

Nearby providers in Plano

Retatrutide status
Phase 3 complete · Not FDA-approvedUpdated October 2, 2026

Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.

Development
Phase 3 complete
FDA status
Submission planned — Q1 2027 (Lilly guidance)
Availability
Not commercially available
Access routes
Clinical trials, or Lilly's expanded access program (physician must apply)

Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)

Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs